



Correction

To cite this article: (2021) Correction, Acta Oncologica, 60:5, 645-645, DOI: [10.1080/0284186X.2021.1885873](https://doi.org/10.1080/0284186X.2021.1885873)

To link to this article: <https://doi.org/10.1080/0284186X.2021.1885873>



Published online: 01 Mar 2021.



Submit your article to this journal [↗](#)



Article views: 485



View related articles [↗](#)



View Crossmark data [↗](#)



Correction

Article title: An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry

Authors: Pouwels X. G. L. V., Ramaekers B. L. T., Geurts S. M. E., Erdkamp F., Vriens B. E. P. J., Aldering K. N. A., van de Wouw A. J., Dercksen M. W., Smilde T. J., Peters N. A. J. B., van Riel J. M. G. H., Pepels M. J., Heijnen-Mommers J., Tjan-Heijnen V. C. G., de Boer M., & Joore M. A.

Journal: *Acta Oncologica*

Bibliometrics: Volume 59, Number 09, pages 1123–1130

DOI: <https://doi.org/10.1080/0284186X.2020.1775289>

During an internal review of the paper after its publication, the authors identified a mistake in one of the input parameters and a typographical error in Table 1. These errors slightly influenced the results but did not affect the conclusions of the paper. The online version of the article has now been corrected to rectify these errors, which are summarized below.

In Table 1 of the paper, the distribution used for modeling the disutility associated with adverse event in the Probabilistic Sensitivity Analysis was described as being '1-Gamma'; this should have been '0-Gamma'. This typographical error had no influence on the results since the latter is used in the technical implementation of the health economic model. Additionally, the parametric distribution for estimating progression-free survival should be 'Gamma' instead of 'Lognormal' and the parameter of the distributions should be the following:

Table 1.

	Mean value	Standard error	Lower value	Upper value
PFS shape – non-eribulin	0.02	0.20	–0.38	0.41
PFS rate – non-eribulin	0.95	0.29	0.39	1.51
PFS: effect eribulin on shape parameter	0.58	0.38	–0.16	1.31
PFS: effect eribulin on rate parameter	0.54	0.29	–0.02	1.11

Effectiveness and adverse events

In this section, the selected curve to model progression-free survival should have been described as a Gamma instead of a Log normal distribution. This is to prevent the progression-free survival curve crossing the overall survival curve, which leads to implausible progression-free survival estimations. Consequently, the results presented in Table 2 have been corrected as follows:

	Eribulin			Non-eribulin			Incremental			
	Total LY	Total QALY	Total costs	Total LY	Total QALY	Total costs	LY	QALY	Costs	ICER per QALY
Deterministic base-case analysis	0.69	0.42	€45,578	0.57	0.36	€29,746	0.12	0.06	€15,832	€252,803
Probabilistic base-case analysis	0.69	0.43	€45,403	0.58	0.37	€29,622	0.11	0.07	€15,782	€239,338
<i>Scenario analyses (deterministic)</i>										
Vial sharing for eribulin	0.69	0.42	€42,484	0.57	0.357	€27,181	0.12	0.063	€15,302	€244,346
No unrelated health care costs in the last year of life	0.69	0.42	€45,304	0.57	0.352	€29,382	0.12	0.064	€15,921	€248,237
Use of Weibull distribution to model PFS*	0.69	0.42	€45,322	0.57	0.357	€29,734	0.12	0.063	€15,588	€248,889
Use of Weibull distribution to model OS	0.69	0.42	€45,801	0.57	0.357	€29,778	0.12	0.063	€16,023	€255,857
Use of log normal distribution to model TTD	0.69	0.42	€44,306	0.57	0.357	€29,746	0.12	0.063	€14,560	€232,485
Alternative utility values from Lopes et al.	0.69	0.44	€45,578	0.57	0.383	€29,746	0.12	0.054	€15,832	€291,872
Use of hazard ratio from EMBRACE for OS and PFS	0.66	0.42	€45,485	0.57	0.357	€29,658	0.08	0.063	€15,826	€252,713
Hospital perspective	0.69	0.41	€41,610	0.57	0.357	€29,746	0.12	0.054	€11,864	€219,424

*A Weibull distribution has been selected because parametric distributions which fit the data better than the gamma distribution leads to implausible PFS estimates (i.e. PFS survival estimates > OS survival estimates).

ICER: incremental cost effectiveness ratio; LY: life years; OS: overall survival; PFS: progression-free survival; QALY: quality-adjusted life years; TTD: time to treatment discontinuation.

Corrections have also been made to Figure 2(a), Figure 3 and Supplemental Material 2.